While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.
By Eleanor Malone and Ian Haydock
While some eyebrows are being raised over the sum Otsuka Pharmaceutical Co. Ltd. is proposing to shell out for...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.
